| Eligibility |
Inclusion Criteria:
1. Age = 18 years old.
2. Patients must have histologically or cytologically confirmed prostate adenocarcinoma,
clinically assessed as localized or with only pelvic lymph node metastasis according
to radiological evaluation, and categorized as high- or very-high risk per the
National Comprehensive Cancer Network (NCCN) guidelines.
3. Patients need to maintain effective luteinizing hormone-releasing hormone analogue
(LHRHa) therapy throughout the study treatment.
4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.
5. Males choosing radical prostatectomy as the primary treatment for prostate cancer.
6. Normal bone marrow function: Absolute neutrophil count = 1.5×10^9/L; platelets =
100×10^9/L; hemoglobin = 90g/L; white blood cell count = 3.6×10^9/L.
7. Normal liver function: Alanine aminotransferase (ALT) or aspartate aminotransferase
(AST) = 2.5 ULN (upper limit of normal), total bilirubin = 1.5 times ULN, Child-Pugh
Class A, serum albumin = 3g/dL.
8. Normal coagulation function: International normalized ratio (INR) = 1.5, activated
partial thromboplastin time (APTT) = 1.5 ULN, prothrombin time (PT) < ULN + 4 seconds.
9. Normal cardiac function: Left ventricular ejection fraction (LVEF) = 50%; QTc < 450ms
for males, < 470ms for females, blood potassium = 3.5mmol/L.
10. Normal blood pressure: Systolic blood pressure < 160mmHg, diastolic blood pressure <
95mmHg, patients with normal blood pressure after appropriate clinical treatment can
be included.
11. Normal kidney function: Serum creatinine = 1.5 ULN, creatinine clearance = 50 mL/min.
12. Patients deemed to have the ability to ejaculate and an active sexual life must agree
to use effective contraception and not to donate sperm from the first administration
of the study drug until 3 months after the last administration.
13. Patients are able to understand and willing to sign the informed consent form.
Patients are able to comply with the study visit schedule and other protocol
requirements.
Exclusion Criteria:
1. Patients with a history of other malignant tumors, myelodysplastic syndrome
(MDS)/acute myeloid leukemia (AML), or who have had other malignant tumors within 5
years before the first dosa (excluding completely resolved in situ cancers and
malignancies deemed by the investigator to progress slowly).
2. Patients who have undergone local treatment for prostate cancer (such as radical
prostatectomy, radiotherapy, or brachytherapy).
3. Patients who have received radiotherapy or major surgery within 3 weeks before the
first dose or participated in another drug clinical trial within 4 weeks before the
first dose.
4. Patients planning to receive any other antitumor therapy during the study treatment.
5. Patients who have received treatment with PARP inhibitors (e.g., fluzoparib, olaparib,
talazoparib, veliparib, niraparib, lucaparib, or others), chemotherapy (e.g.,
docetaxel, cisplatin, carboplatin, oxaliplatin, or others), mitoxantrone,
cyclophosphamide, CYP17 inhibitors such as ketoconazole, conventional anti-androgen
therapy (luteinizing hormone-releasing hormone [LHRH] agonists/antagonists,
bicalutamide, nilutamide), novel hormonal therapy (e.g., abiraterone, enzalutamide,
apalutamide), or immunotherapy (e.g., sipuleucel-T vaccine, ipilimumab). Patients who
have received conventional anti-androgen therapy or abiraterone for no more than 1
month are allowed to enroll.
6. Patients who have previous treated with strong CYP3A inhibitors (e.g., itraconazole,
telithromycin, clarithromycin, ritonavir, cobicistat, indinavir, saquinavir,
nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g., ciprofloxacin,
erythromycin, diltiazem, fluconazole, verapamil). The washout period before the first
dose should be at least 2 weeks.
7. Patients who have previous treated with strong CYP3A inducers (e.g., phenobarbital,
phenytoin, rifampin, rifabutin, rifapentine, carbamazepine, nevirapine) or moderate
CYP3A inducers (e.g., bosentan, efavirenz, modafinil). The washout period before the
first dose should be at least 5 weeks for phenobarbital or enzalutamide and 3 weeks
for other drugs.
8. Habitual drinking grapefruit juice or excessive tea, coffee, and/or
caffeine-containing beverages, which cannot be discontinued during the study.
9. Inability to discontinue the use of medications that may affect P-glycoprotein (P-gp)
during the study, including but not limited to amiodarone, carvedilol, clarithromycin,
delavirdine, erythromycin, lapatinib, lopinavir, nelfinavir, propranolol, quinidine,
ranolazine, tipranavir, and verapamil.
10. Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency
syndrome (AIDS)-related diseases, active or symptomatic viral hepatitis, or chronic
liver disease (HBV viral load = 10^4 copies/mL, HCV viral load = 10^3 copies/mL).
11. Clinically significant heart disease, such as New York Heart Association (NYHA) Class
III-IV heart failure, myocardial infarction within the past 6 months, severe or
unstable angina, or recent ventricular arrhythmias.
12. Preexisting duodenal stents or any gastrointestinal disorder or defect that the
investigator believes would interfere with drug absorption.
13. Habitual constipation or diarrhea, irritable bowel syndrome, or inflammatory bowel
disease; intra-abdominal fistula, gastrointestinal perforation, or abdominal abscess
within the past 6 months, requiring blood transfusion for gastrointestinal bleeding.
14. Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors
affecting medication intake and absorption.
15. History of asthma induced by nonsteroidal anti-inflammatory drugs (NSAIDs) or
classified as "mild persistent" or more severe asthma history (symptoms = 2 days per
week).
16. History of uncontrolled pituitary or adrenal dysfunction, existing gonadal
dysfunction, or severe hypogonadism.
17. Contraindications to the use of prednisone (corticosteroids) such as active infections
or other lesions.
18. Any chronic disease requiring corticosteroid therapy at doses exceeding "prednisone
5mg, twice daily."
19. Allergy or intolerance to the active ingredients of fluzoparib, abiraterone, or
prednisone.
20. History of neurological and psychiatric disorders such as dementia, epilepsy, or
seizure susceptibility.
21. According to the investigator's judgment, there are severe concurrent diseases (such
as severe diabetes, thyroid disease, and psychiatric illness, etc.) or unstable
medical, psychological, or other conditions (including laboratory abnormalities) that
may pose a serious risk to the subject's safety, affect the subject's completion of
the study, or affect the study protocol and follow-up schedule.
22. Unsuitable for participation in this clinical trial for any reason according to the
investigator's judgment.
|
